Albiglutide Bests Placebo for Prevention of MACE in Type 2 Diabetic Patients with CVD

Albiglutide was superior to placebo for the reduction of major adverse cardiac events (MACE) in patients with type 2 diabetes and cardiovascular disease (CVD), new study results indicate.  

The authors, publishing in The Lancet, conducted a double-blind, randomized, placebo-controlled study that included 9,463 patients who were randomly assigned (1:1) to either receive albiglutide (n=4,731) or placebo (n=4,732). The primary study outcome was first occurrence of cardiovascular death, myocardial infarction, or stroke. Median follow-up was 1.6 years.  

According to the results, there were 611 total occurrences of the primary endpoint (338 of 4,731 [7%] in the albiglutide group versus 428 of 4,732 [9%] patients in the placebo group; HR=0.78, 95% CI, 0.68 to 0.90; P<0.0001 for noninferiority; P=0.0006 for superiority), indicating superiority for albiglutide. Pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and other serious adverse events were not different between study groups. 

“In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events,” the researchers wrote in their aabstract. “Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.” 

Source: The Lancet